Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 4/20 | 0.47 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277361 | 0.89 | TACR1 (0.53) | TACR1OPRD1OPRK1CCR5SCD5 | |
| SCHEMBL1207178 | 0.84 | TACR1 (0.55) | TACR1OPRD1OPRK1CCR5SCD5 | |
| SCHEMBL31327719 | 0.84 | TACR1 (0.55) | TACR1OPRD1OPRK1CCR5SCD5 | |
| SCHEMBL7000547 | 0.83 | TACR1 (0.54) | TACR1OPRD1OPRK1CCR5SCD5 | |
| SCHEMBL3272198 | 0.82 | TACR1 (0.58) | TACR1OPRD1OPRK1CCR5TSHR | |
| SCHEMBL1206023 | 0.81 | TACR1 (0.53) | TACR1OPRD1OPRK1CCR5SCD5 | |
| SCHEMBL2270783 | 0.80 | TACR1 (0.61) | TACR1OPRD1OPRK1CCR5TSHR | |
| SCHEMBL19226428 | 0.79 | TACR1 (0.60) | TACR1OPRD1OPRK1CCR5TSHR | |
| SCHEMBL557992 | 0.79 | TACR1 (0.60) | TACR1OPRD1OPRK1CCR5TSHR | |
| SCHEMBL17886658 | 0.79 | TACR1 (0.63) | TACR1OPRD1OPRK1CCR5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| US-20070173525-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| US-20050239815-A1 | Tyrosine kinase inhibitors | KIM ANNETTE J | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173525-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | TACR1 274/4885OPRD1 1749/4885OPRK1 600/4885 |
| US-20050239815-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | TACR1 274/4885OPRD1 1749/4885OPRK1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.